Estrella Immunopharma Inc
ESLAW0.058USD
-0.004-5.84%
Close 01/16, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Estrella Immunopharma Inc Company
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).
Estrella Immunopharma Inc Info
Ticker SymbolESLAW
Company nameEstrella Immunopharma Inc
IPO dateJul 19, 2021
CEODr. Cheng Liu, Ph.D.
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address5858 Horton St, Suite 370
CityEMERYVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94608
Phone15103189098
Websitehttps://www.estrellabio.com/
Ticker SymbolESLAW
IPO dateJul 19, 2021
CEODr. Cheng Liu, Ph.D.
Company Executives of Estrella Immunopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jia Dengyao
Mr. Jia Dengyao
Director
Director
--
--
Dr. Marsha Roberts
Dr. Marsha Roberts
Independent Director
Independent Director
--
--
Mr. Fan Wu
Mr. Fan Wu
Independent Director
Independent Director
--
--
Ms. Janelle Wu
Ms. Janelle Wu
Independent Director
Independent Director
--
--
Ms. Pei Xu
Ms. Pei Xu
Independent Director
Independent Director
--
--
Ms. Hong Zhang
Ms. Hong Zhang
Chairman of the Board
Chairman of the Board
--
--
Dr. Cheng Liu, Ph.D.
Dr. Cheng Liu, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Xu
Mr. Peter Xu
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jia Dengyao
Mr. Jia Dengyao
Director
Director
--
--
Dr. Marsha Roberts
Dr. Marsha Roberts
Independent Director
Independent Director
--
--
Mr. Fan Wu
Mr. Fan Wu
Independent Director
Independent Director
--
--
Ms. Janelle Wu
Ms. Janelle Wu
Independent Director
Independent Director
--
--
Ms. Pei Xu
Ms. Pei Xu
Independent Director
Independent Director
--
--
Ms. Hong Zhang
Ms. Hong Zhang
Chairman of the Board
Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
19
746.71K
0.00%
-415.62K
2025Q3
20
771.61K
0.00%
--
2025Q2
26
771.61K
0.00%
-298.02K
2025Q1
26
1.07M
0.00%
-784.04K
2024Q4
26
1.18M
0.00%
-51.63K
2024Q3
26
1.23M
0.00%
+189.21K
2024Q2
26
1.04M
0.00%
-21.28K
2024Q1
26
1.06M
0.00%
-787.77K
2023Q4
26
1.06M
0.00%
+173.07K
2023Q3
23
886.48K
0.00%
-388.45K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Clear Street Group Inc
33.98K
0%
+33.98K
--
Sep 30, 2025
Robinson Capital Management, LLC
--
0%
-11.80K
-100.00%
Dec 31, 2024
Highbridge Capital Management, LLC
--
0%
-338.19K
-100.00%
Jun 30, 2025
Boothbay Fund Management, LLC
189.90K
0%
--
--
Sep 30, 2025
ATW Spac Management LLC
183.10K
0%
--
--
Sep 30, 2025
Walleye Trading, LLC
--
0%
-72.83K
-100.00%
Sep 30, 2025
D. E. Shaw & Co., L.P.
87.50K
0%
--
--
Sep 30, 2025
Skyview Investment Advisors, LLC
62.50K
0%
--
--
Jun 30, 2025
Yakira Capital Management, Inc.
46.48K
0%
--
--
Sep 30, 2025
Whitebox Advisors, L.L.C.
42.29K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Estrella Immunopharma Inc?
The top five shareholders of Estrella Immunopharma Inc are:
Clear Street Group Inc holds 33.98K shares, accounting for 0.00% of the total shares.
Robinson Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Highbridge Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Boothbay Fund Management, LLC holds 189.90K shares, accounting for 0.00% of the total shares.
ATW Spac Management LLC holds 183.10K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 33.98K shares, accounting for 0.00% of the total shares.
Robinson Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Highbridge Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Boothbay Fund Management, LLC holds 189.90K shares, accounting for 0.00% of the total shares.
ATW Spac Management LLC holds 183.10K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Estrella Immunopharma Inc?
The top three shareholder types of Estrella Immunopharma Inc are:
Other
Other
How many institutions hold shares of Estrella Immunopharma Inc (ESLAW)?
As of 2025Q4, 19 institutions hold shares of Estrella Immunopharma Inc, with a combined market value of approximately 746.71K, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Estrella Immunopharma Inc?
In --, the -- business generated the highest revenue for Estrella Immunopharma Inc, amounting to -- and accounting for --% of total revenue.
